Dr. Sabine Mai, a co-founder and principle inventor of 3D Signatures (TSX-V:DXD; OTCQB:TDSGF; FSE:3D0), will present on Feb. 21 at the International Molecular Medicine Tri-Conference in San Francisco, results of a prospective blood-based prostate cancer pilot study using the company’s TeloView software platform.
Based on blinded blood samples, TeloView correctly predicted the stability and aggressiveness of disease for each of the study’s 50 intermediate-risk prostate cancer patients.
“These results are extremely encouraging,” Jason Flowerday, CEO of 3DS, said in a statement.
“We believe that the TeloView software platform is a disruptive technology. It is based on a universal structural biomarker, 3D telomere organization, that has generated impressive results across a number of diseases, with prostate cancer being one of our highest priorities,” he added.
In previous clinical research, TeloView also demonstrated the ability to identify and profile multiple circulating tumor cell clones within a single patient as well as the ability to monitor and quantify changes to 3D telomere profiles as a result of treatment.
Based on clinical data produced by Dr. Mai and her colleagues, 3DS believes that TeloView is a promising candidate for development as an accurate, blood-based risk-assessment and monitoring platform for prostate cancer.
TeloView will be included in a multicenter Canada-wide prostate cancer clinical trial, known as PRECISE, to identify and monitor prostate cancer patients suitable for active surveillance.
